The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011
Open accessAbstract
Background—: Little is known regarding the adoption of direct thrombin inhibitors in clinical practice. We examine trends in oral anticoagulation for the prevention of thromboembolism in the United States. Methods and Results—: We used the IMS Health National Disease and Therapeutic Index, a nationally representative audit of office-based providers, to quantify patterns of oral anticoagulant use among all subjects and stratified by clinical indication. We quantified oral anticoagulant expenditures using the IMS Health National Prescription Audit. Between 2007 and 2011, warfarin treatment visits declined from ≈2.1 million (M) quarterly visits to ≈1.6M visits. Dabigatran use increased from 0.062M quarterly visits (2010Q4) to 0.363M visits (2011Q4), reflecting its increasing share of oral anticoagulant visits from 3.1% to 18.9%. In contrast to warfarin, the majority of dabigatran visits have been for atrial fibrillation, though this proportion decreased from 92% (2010Q4) to 63% (2011Q4), with concomitant increases in dabigatran’s off-label use. Among atrial fibrillation visits, warfarin use decreased from 55.8% visits (2010Q4) to 44.4% (2011Q4), whereas dabigatran use increased from 4.0% to 16.9%. Of atrial fibrillation visits, the fraction not treated with any oral anticoagulants has remained unchanged at ≈40%. Expenditures related to dabigatran increased rapidly from $16M in 2010Q4 to $166M in 2011Q4, exceeding expenditures on warfarin ($144M) in 2011Q4. Conclusions—: Dabigatran has been rapidly adopted into ambulatory practice in the United States, primarily for treatment of atrial fibrillation, but increasingly for off-label indications. We did not find evidence that it has increased overall atrial fibrillation treatment rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
The Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Wann, L. S., Curtis, A. B., January, C. T., Ellenbogen, K. A., Lowe, J. E., Estes, N. A. M., Page, R. L., Ezekowitz, M. D., Slotwiner, D. J., Jackman, W. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3181fa3cf4 · Cited by 1,336
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.009 · Cited by 1,158
Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081 · cited 1×
“The RE-LY trial reported a lower risk of major bleeding for dabigatran compared with warfarin among individuals <75 years of age, but a nonstatistically significant trend toward an increased risk of major bleeding among those ≥75 years of age.(36) From a clinic perspective, however, dabigatran use in the most elderly…”
BackgroundUnderuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
Ogilvie, I. M., Newton, N., Welner, S. A., Cowell, W., & Lip, G. Y. H. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.025 · Cited by 927
Antithrombotic Therapy for Atrial Fibrillation
You, J. J., Singer, D. E., Howard, P. A., Lane, D. A., Eckman, M. H., Fang, M. C., Hylek, E. M., Schulman, S., Go, A. S., Hughes, M., et al. (2012) · Chest · doi:10.1378/chest.11-2304 · Cited by 918
Go, A. S., Hylek, E. M., Borowsky, L. H., Phillips, K. A., Selby, J. V., & Singer, D. E. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-12-199912210-00004 · Cited by 585
Miniño, A., Murphy, S. L., Xu, J., & Kochanek, K. D. (2011) · PubMed · Cited by 473
Uchino, K. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.1666 · Cited by 431
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
Freeman, J. V., Zhu, R. P., Owens, D. K., Garber, A. M., Hutton, D. W., Go, A. S., Wang, P. J., & Turakhia, M. P. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00289 · Cited by 429
Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
Shah, S. V., & Gage, B. F. (2011) · Circulation · doi:10.1161/circulationaha.110.985655 · Cited by 337
The underutilization of cardiacmedications of proven benefit, 1990 to 2002
Stafford, R. S., & Radley, D. C. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02670-0 · Cited by 286
Self-citationDeaths: leading causes for 2004.
Heron, M. P. (2007) · PubMed · Cited by 234
Oldgren, J., Alings, M., Darius, H., Diener, H.-C., Eikelboom, J., Ezekowitz, M. D., Kamensky, G., Reilly, P. A., Yang, S., Yusuf, S., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-10-201111150-00004 · Cited by 198
Wann, L. S., Curtis, A. B., Ellenbogen, K. A., Estes, N. A. M., Ezekowitz, M. D., Jackman, W. M., January, C. T., Lowe, J. E., Page, R. L., Slotwiner, D. J., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.010 · Cited by 175
Hachamovitch, R. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.121 · Cited by 168
Deaths: leading causes for 2007.
Heron, M. P. (2011) · PubMed · Cited by 168
Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk?
ZIMETBAUM, P. J., Thosani, A. J., Yu, H.-T., Xiong, Y., Lin, J., Kothawala, P., & Emons, M. F. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.015 · Cited by 155
Friedman, R. J., Dahl, O. E., Rosencher, N., Caprini, J. A., Kurth, A. A., Francis, C. W., Clemens, A., Hantel, S., Schnee, J. M., & Eriksson, B. I. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.03.021 · Cited by 141
Gross, C. P., Vogel, E. W., Dhond, A. J., Marple, C. B., Edwards, R. A., Hauch, O., Demers, E. A., & Ezekowitz, M. D. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80167-4 · Cited by 113
Schulman, S., Parpia, S., Stewart, C., Rudd-Scott, L., Julian, J. A., & Levine, M. N. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-10-201111150-00003 · Cited by 86
Anticoagulant Use for Atrial Fibrillation in the Elderly
Brophy, M. T., Snyder, K. E., Gaehde, S. A., Ives, C., GAGNON, D. R., & Fiore, L. D. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52314.x · Cited by 83
Does Comparative Effectiveness Have a Comparative Edge?
Alexander, G. C., & Stafford, R. S. (2009) · JAMA · doi:10.1001/jama.2009.851 · Cited by 60
Self-citationPhysician Consideration of Patients' Out-of-Pocket Costs in Making Common Clinical Decisions
Pham, H. H. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.7.663 · Cited by 39
National Trends in Ambulatory Asthma Treatment, 1997–2009
Higashi, A. S., Zhu, S., Stafford, R. S., & Alexander, G. C. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1796-4 · Cited by 37
Self-citationSix strategies to identify and assist patients burdened by out-of-pocket prescription costs.
Alexander, G. C., & Tseng, C.-W. (2004) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.71.5.433 · Cited by 34
Self-citationEnhancing Prescription Drug Innovation and Adoption
Alexander, G. C., O'connor, A., & Stafford, R. S. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-12-201106210-00012 · Cited by 21
Self-citation
Cited by
Reddy, V. Y., Sievert, H., Halperin, J., Doshi, S. K., Buchbinder, M., Neuzil, P., Huber, K., Whisenant, B., Kar, S., Swarup, V., et al. (2014) · JAMA · doi:10.1001/jama.2014.15192 · Cited by 1,018
“of Enrollments]): Europe: Petr Neuzil (Na Homolce Hospital, Prague, Czech Republic [32]); Horst Sievert (Cardiovascular Center Frankfurt, Sankt Katharinen, Frankfurt, Germany [52]); Sven Mobius-Winkler (Herzzentrum Leipzig, Leipzig, Germany [35]); Peter Sick (Krankenhaus der Barmherzigen Bruder, Regensburg, Germany [8…”
BackgroundGlobal epidemiology of atrial fibrillation
Rahman, F., Kwan, G. F., & Benjamin, E. J. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.118 · Cited by 731
National trends in ambulatory oral anticoagulant use
Barnes, G. D., Lucas, E., Alexander, G. C., & Goldberger, Z. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.044 · Cited by 598
Self-citationTzikas, A., Shakir, S., Gafoor, S., Omran, H., Berti, S., Santoro, G., Kefer, J., Landmesser, U., Nielsen-Kudsk, J. E., Cruz-Gonzalez, I., et al. (2016) · EuroIntervention · doi:10.4244/eijy15m01_06 · Cited by 546
Abraham, N. S., Singh, S., Alexander, G. C., Heien, H., Haas, L. R., Crown, W., & Shah, N. D. (2015) · BMJ · doi:10.1136/bmj.h1857 · Cited by 347
Self-citation
Metadata
- Authors
- Kirley, K., Qato, D. M., Kornfield, R., Stafford, R. S., & Alexander, G. C.
- Venue
- Circulation: Cardiovascular Quality and Outcomes
- Published
- 2012-09
- Volume
- 5
- Issue
- 5
- Pages
- 615-621
- ISSN
- 1941-7705 (ISSN-L)
- 1941-7713
- OpenAlex
- W2106828417
- Cited by
- 311
- References
- 33
- FWCI
- 19.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.